Showing results (821-830 of 936) with videos related to

Sort By:
Pageof 94
Virology Journal|December 6, 2013
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in miceGeorge M Warimwe, Gema Lorenzo, Elena Lopez-Gil, et al.
Contemporary Clinical Trials|March 18, 2023
Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected dataArchie Macnair, Matthew Nankivell, Macey L Murray, et al.
Plos One|January 31, 2008
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trialFiona M Thompson, David W Porter, Shinji L Okitsu, et al.
Nature Communications|May 14, 2016
Crystal structure of an invertebrate cytolysin pore reveals unique properties and mechanism of assemblyMarjetka Podobnik, Peter Savory, Nejc Rojko, et al.
Vaccines|March 27, 2019
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell LinePedro M Folegatti, Duncan Bellamy, Amy Flaxman, et al.
Research Square|February 23, 2022
Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster modelNeeltje van Doremalen, Jonathan E Schulz, Danielle R Adney, et al.
AIDS (London, England)|December 8, 2022
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South AfricaWilliam C McMahon, Gaurav Kwatra, Alane Izu, et al.
European Journal of Clinical Nutrition|September 11, 2014
Inflammation profile in overweight/obese adolescents in Europe: an analysis in relation to iron statusM Ferrari, M Cuenca-García, J Valtueña, et al.
Nature Communications|August 8, 2022
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variantsNeeltje van Doremalen, Jonathan E Schulz, Danielle R Adney, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignanciesA M Hussein, W P Petros, M Ross, et al.
Pageof 94